CCTG Presentations at American Society of Hematology Annual Meeting (ASH) and San Antonio Breast Cancer Symposium

Wednesday, January 9, 2019

SABCS 2018 Spotlight session drawing crowds - Featuring CCTG MA38 poster

Congratulations to the researchers who presented abstracts at two important International research meetings at the end of 2018.

- Abstracts presented at the 60th ASH Annual Meeting and Exposition
- MCRN-003 / CCTG MYX.1 - A Single Arm Phase II Study of High-Dose Weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies (conducted in collaboration with the Myeloma Canada Research Network)
- Alliance A041202 / CCTG CLC.2 – A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients ≥ 65 years of age) with Chronic Lymphocytic Leukemia (CLL)
- Alliance A10603 / CCTG ALC.2 - A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/ Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PK412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)
- CCTG LY.10 - A Phase II Study of Gemcitabine, Dexamethasone, and Cisplatin (GDP) in Patients With Either Hodgkin's Disease or Aggressive Histology Non-Hodgkin's Lymphoma Which is Relapsed or Refractory

- Abstracts presented at the Annual San Antonio Breast Cancer Symposium
- Spotlight Session: Developmental Therapeutics - CCTG MA.38 - Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer
- Poster Session: Treatment: Adjuvant Therapy - SWOG S0307/CCTG MAC.9 - Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
- Spotlight Session: Next Steps in HER2 Targeted Therapy: CCTG MA.31 - A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer
- Poster Session: Epidemiology, Risk, and Prevention: CCTG MAP.3 - A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
- Oral Session: General Session: ECOG PACCT-1/ MAC.12 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial
- Oral Session: General Session: Regional lymph node irradiation in early stage breast cancer: An EBCTCG metaanalysis of 13,000 women in 14 trials
- Oral Session: General Session: Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women
Caner Saygin, MD @CanerSaygin · 2 Dec 2018

Frank Rucker shows that the site of FLT3-ITD matters: ITDs involving beta-1 sheet of TKD are associated with inferior outcome and may not be fully addressed with midostaurin. Would be interesting to see the effect of newer FLTi for these pts.

#ASH18